Reference is made to the stock exchange notice dated 21 December 2009 and the prospectus dated 21 December 2009 regarding a subsequent offering of up to 8,000,000 offer shares in NorDiag ASA ("NorDiag" or the "Company"), each with a nominal value of NOK 1.00, at a subscription price of NOK 1.00 per share with subscription rights for shareholders of the Company as of 25 November 2009, except shareholders who were invited to participate in the private placement completed on 25 November 2009. The subscription period in the subsequent offering in NorDiag expired at 17:30 (CET) on 12 January 2010. At the end of the subscription period, NorDiag had received subscriptions for a total of 19,357,830 new shares. Consequently, the subsequent offering was oversubscribed by approximately 142 per cent. Approximately 71 per cent of the new shares offered (approximately 5.7 million shares) were subscribed by exercising subscription rights. Approximately 171 per cent of the new shares on offer (approximately 13.7 million shares) were subscribed for through oversubscription by holders of subscription rights or by subscribers without subscription rights. In a board meeting 18 January 2010, the Board of Directors of NorDiag approved the final allocation of the shares offered in the subsequent offering based on the allocation criteria set out in the prospectus dated 21 December 2009. A total of 8,000,000 new shares have been allocated. Approximately 5.7 million new shares have been allocated to subscribers on the basis of exercised subscription rights. Approximately 2.3 million new shares have been allocated to holders of subscription rights on basis of oversubscription. No allocation has been made to subscribers without subscription rights. Letters of notification of new shares allocated and the corresponding subscription amount to be paid by each subscriber are expected to be distributed from the VPS on 19 January 2010. Payment for the allocated shares falls due on 21 January 2010 in accordance with the payment procedures described in the prospectus. The new shares may not be transferred or traded before they are fully paid and the share capital increase pertaining to the subsequent offering has been registered with the Norwegian Register of Business Enterprises. It is expected that the share capital increase will be registered in the Norwegian Register of Business Enterprises on or about 26 January 2010 and that the new shares will be admitted to trading on the Oslo Stock Exchange on the same day. Through the subsequent offering, NorDiag will receive proceeds of NOK 8,000,000 before the deduction of transaction costs. Following registration of the share capital increase in the Norwegian Register of Business Enterprises, the Company's share capital will be NOK 62,065,282 divided into 62,065,282 shares, each with a nominal value of NOK 1.00. DnB NOR Markets acted as manager in the subsequent offering. Contact: Contact:      CEO Mårten Wigstøl        Phone: +47 911 65775                    CFO Tone Kvåle              Phone: +47 915 19576 About NorDiag: NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and tests) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and is the fastest growing field within diagnostics. The company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 40.1 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD. For further information, please see This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act) [HUG#1374402]